Philip Sassene
Scientific Director Novo Nordisk
Philip Sassene is an experienced pharmaceutical R&D leader responsible for shaping scientific strategy, evaluating emerging technologies and external partnerships, and driving innovation across multidisciplinary drug development programs. He has extensive expertise in leading cross-functional project teams, conducting scientific and business due diligence, and establishing strategic collaborations with both internal stakeholders and external partners. Philip is also highly skilled in stakeholder engagement, working closely with senior leadership to align scientific priorities with broader business objectives and accelerate the advancement of high-impact development programs.
Seminars
How close are we to making oral peptide therapeutics the new standard of care?
As demand grows for more convenient, patient-friendly therapies, how can developers overcome the persistent challenges of poor bioavailability, gastrointestinal degradation and limited permeability without compromising safety or scalability? Is it time to move beyond traditional permeation enhancers towards intrinsically orally available peptides? And which formulation strategies are best positioned to deliver clinically meaningful improvements while supporting successful translation to the clinic?
In this workshop:
- Discover how to increase peptide bioavailability from single digits to 20-30% by modifying physical properties rather than relying on traditional permeation enhancers
- Learn formulation strategies that enable scalable, cost-efficient oral delivery with favourable regulatory safety profiles
- Understand how double-digit bioavailability can be achieved with oral formulations entirely based on FDA approved excipients and peptide design
- Gain insights into selecting the right formulation technology early in preclinical development to avoid costly late-stage failures
- Master the critical transition from injectable to oral modalities to capture multi billiondollar market opportunities.
